IXHL · Incannex Healthcare Inc. · Investor Relations

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approximately $70 million in cash and no debt, including more than A$11.2 million in

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc.

Completion of more than A$11.2 million in non-dilutive capital received under the Australian Government’s R&D Tax Incentive Program further strengthens Company’s balance sheet and financial flexibility NEW YORK and MELBOURNE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc.

First clinical sites approved and actively screening potential participants Represents another major milestone in the advancement of IHL-42X towards Phase III development IHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical need in

MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the United States

In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026 NEW YORK and MELBOURNE, Australia,

MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to

Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activated MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc.

Recognition highlights strong clinical progress and growing global validation of Incannex’s innovative approach to treating obstructive sleep apnea MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company

Company’s oral synthetic psilocybin program advances within significantly improved regulatory environment MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination